This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Detels and colleagues¹ reported that 141 (49%) of 288 patients followed up in a variety of health care settings between July 1995 and July 1997 were receiving potent antiretroviral therapy (PART). We have been asked repeatedly whether financial considerations impede prescribing PART in a managed-care setting. To investigate this question, we reviewed the computerized and hard copy medical records of the 1839 patients who tested positive for the human immunodeficiency virus (HIV) who attend either the San Francisco or Hayward facilities of Kaiser Permanente Medical Care Program, a not-for-profit health plan. We determined whether those patients having CD4⁺ lymphocyte counts less than 500/mm³ (0.50 x 10⁹/L) or HIV RNA levels of 10,000 copies/mL or greater had received a supply of 3 or more antiretroviral medications for 2 or more consecutive months between January 1, 1996, and June 30, 1998.

There were 1389 patients who were . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection Duration
Roger Detels, Alvaro Muñoz, Glen McFarlane, Lawrence A. Kingsley, Joseph B. Margolick, Janis Giorgi, Lewis K. Schrager, John P. Phair, and for the Multicenter AIDS Cohort Study Investigators
JAMA. 1998;280(17):1497-1503.
ABSTRACT | FULL TEXT